As health complications and deaths from alcohol use disorder (AUD) increase in the United States, it is critical that people ...

The polygenic score calculated using concordant single-nucleotide variants may be a method to evaluate risk for alcohol use ...

Study represents the first clinical application of CMND-100, the Company’s proprietary drug platform Vancouver, Canada, March 18, 2025 (GLOBE ...

A phase 2 trial shows significant reduction in drinks per drinking day and weekly alcohol craving with low-dose semaglutide. HealthDay News — Low-dose semaglutide seems to reduce craving and certain ...

Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) ("Filament" or the "Company"), a clinical‐stage natural psychedelic drug development company, today announced positive data from an open-label ...

Altimmune plans Phase 2 trials in 2025 for pemvidutide in alcohol use disorder and liver disease, highlighting weight loss ...

The Maryland-based biopharma joins Eli Lilly and Novo Nordisk in trialing a GLP-1 agonist for alcohol- and liver-related ...

Semaglutide shows promise in reducing alcohol cravings and consumption. Could it be a future treatment for AUD?

Study represents the first clinical application of CMND-100, the Company's proprietary drug platform Vancouver, Canada, March 18, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: ...

Screening should be conducted in patients exhibiting signs or symptoms of AUD. While there are multiple screening methods, the AUDIT-C (Alcohol Use Disorders Identification Test-Consumption ...

Alcohol use disorder (AUD) is one of the most common substance use disorders contributing to both behavioral and cognitive impairments in patients with AUD. Recent neuroimaging studies point out that ...